Next Article in Journal
Bioinformatics for Marine Products: An Overview of Resources, Bottlenecks, and Perspectives
Previous Article in Journal
Preparation and Properties of Minocycline-Loaded Carboxymethyl Chitosan Gel/Alginate Nonwovens Composite Wound Dressings
Previous Article in Special Issue
Stereo-Selective Pharmacokinetics of Ilimaquinone Epimers Extracted from a Marine Sponge in Rats
Open AccessArticle

Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach

1
St. Petersburg State Chemical Pharmaceutical University, Prof. Popov, 14, 197376 Saint-Petersburg, Russia
2
St. Petersburg Institute of Pharmacy, Leningrad Region, Vsevolozhsky District, Kuzmolovo P 245, 188663 Saint-Petersburg, Russia
3
Vetcore facility for Research, University of Veterinary Medicine, Veterinärplatz 1. 1210 Wien, Austria
4
Institute of Animal Nutrition and Functional Plant Compounds, University of Veterinary Medicine, Veterinärplatz 1. 1210 Wien, Austria
*
Author to whom correspondence should be addressed.
Mar. Drugs 2019, 17(10), 577; https://doi.org/10.3390/md17100577
Received: 5 September 2019 / Revised: 4 October 2019 / Accepted: 8 October 2019 / Published: 11 October 2019
(This article belongs to the Special Issue Pharmacokinetic Research of Marine Drugs)
A glycopeptide fraction (GPF) from internal organs of green sea urchins (Strongylocentrotus droebachiensis Müller, Strongylocentrotidae) has been reported to be an effective bronchitis treatment. In this study, we evaluated the pharmacokinetic and tissue distribution of GPF, following single and repeated intranasal (i/n) administration over the course of seven days in rats. The method measuring lactate dehydrogenase as biomarker was used to analyse the plasma and tissue concentrations of GPF. GPF appears in the plasma 15 min after single i/n administration (100 µg/kg) and reaches its maximum at 45 min. The area under the curve (AUC)0–24 and Cmax were similar using both i/n and intravenous administration, while mean residence time (MRT) and T1/2 after i/n administration were significantly higher compared with intravenous (i/v) administration. The absolute bioavailability of GPF after i/n administration was 89%. The values of tissue availability (ft) provided evidence about the highest concentration of GPF in the nose mucosa (ft = 34.9), followed by spleen (ft = 4.1), adrenal glands (ft = 3.8), striated muscle (ft = 1.8), kidneys (ft = 0.5), and liver (ft = 0.3). After repeated dose administration, GPF exhibited significantly higher AUC0–24 and MRT, indicating its accumulation in the plasma. View Full-Text
Keywords: Strongylocentrotus droebachiensis; rats; plasma; nose mucosa; liver; kidney; spleen; striated muscle Strongylocentrotus droebachiensis; rats; plasma; nose mucosa; liver; kidney; spleen; striated muscle
Show Figures

Figure 1

MDPI and ACS Style

Shikov, A.N.; Pozharitskaya, O.N.; Faustova, N.M.; Kosman, V.M.; Makarov, V.G.; Razzazi-Fazeli, E.; Novak, J. Pharmacokinetic Study of Bioactive Glycopeptide from Strongylocentrotus droebachiensis After Intranasal Administration to Rats Using Biomarker Approach. Mar. Drugs 2019, 17, 577.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop